Disc Medicine (IRON) Income from Continuing Operations (2020 - 2026)
Disc Medicine (IRON) posted quarterly Income from Continuing Operations of 59532000.0 for Q2 2026, down 7.76% year-over-year from 64537584.95 in Q2 2025, and up 6.33% quarter-over-quarter from 63553000.0 in Q1 2026.
Powered by 
Analysis
Disc Medicine (IRON) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Income from Continuing Operations for 7 consecutive years, with 59532000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 7.76% year-over-year to 59532000.0; the TTM figure through Jun 2026 stood at 201422000.0 (down 38.56% YoY), while the FY2025 annual figure was 167669000.0, down 53.32% from the prior year.
- Income from Continuing Operations advanced to 59532000.0 in Q2 2026 per IRON's latest filing, from 63553000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9580000.0 in Q2 2022 and bottomed at 63553000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 29080055.56 across 5 years, with a median of 24949000.0 in 2023.
- On a YoY basis, Income from Continuing Operations climbed as much as 46.27% in 2022 and fell as far as 155.29% in 2022.
- Disc Medicine's Income from Continuing Operations stood at 11244000.0 in 2022, then slumped by 109.41% to 23546000.0 in 2023, then retreated by 25.01% to 29436000.0 in 2024, then surged by 45.59% to 16016000.0 in 2025, then sank by 271.7% to 59532000.0 in 2026.
- Business Quant data shows IRON's Income from Continuing Operations at 59532000.0 in Q2 2026, 63553000.0 in Q1 2026, and 16016000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Disc Medicine | 3.09 Bn | 3.09 Bn | - | -59.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -59.53 Mn |
| Mar 31, 2026 | -63.55 Mn |
| Dec 31, 2025 | -16.02 Mn |
| Sep 30, 2025 | -62.32 Mn |
| Jun 30, 2025 | -55.25 Mn |
| Mar 31, 2025 | -34.09 Mn |
| Dec 31, 2024 | -29.44 Mn |
| Sep 30, 2024 | -26.60 Mn |
| Jun 30, 2024 | -26.35 Mn |
| Mar 31, 2024 | -27.04 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -14.10 Mn |
| Jun 30, 2023 | -15.92 Mn |
| Mar 31, 2023 | -22.86 Mn |
| Dec 31, 2022 | -11.24 Mn |
| Sep 30, 2022 | -16.15 Mn |
| Jun 30, 2022 | -9.58 Mn |
| Mar 31, 2022 | -9.85 Mn |
| Dec 31, 2021 | 20.25 Mn |
| Sep 30, 2021 | -18.55 Mn |